title: Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma.
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: L
authors.initials: L
authors.lastname: Ratner
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: D
authors.initials: D
authors.lastname: Rauch
authors.affiliation: Department of Genetics, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: H
authors.initials: H
authors.lastname: Abel
authors.affiliation: Viral Immunology Section, Neuroimmunology and Neurovirology Division, NINDS, NIH, Bethesda, MD, USA.
authors.forename: B
authors.initials: B
authors.lastname: Caruso
authors.affiliation: Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: A
authors.initials: A
authors.lastname: Noy
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: S K
authors.initials: SK
authors.lastname: Barta
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
authors.forename: S
authors.initials: S
authors.lastname: Parekh
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Miami School of Medicine, Miami, FL, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Ramos
authors.affiliation: Division of Hematologic Malignancies, Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
authors.forename: R
authors.initials: R
authors.lastname: Ambinder
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Columbia University Medical Center, New York, NY, USA.
authors.forename: A
authors.initials: A
authors.lastname: Phillips
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: J
authors.initials: J
authors.lastname: Harding
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: H H
authors.initials: HH
authors.lastname: Baydoun
authors.affiliation: Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: X
authors.initials: X
authors.lastname: Cheng
authors.affiliation: Viral Immunology Section, Neuroimmunology and Neurovirology Division, NINDS, NIH, Bethesda, MD, USA.
authors.forename: S
authors.initials: S
authors.lastname: Jacobson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D015490:HTLV-I Infections / Q000150:complications* / Q000821:virology; D015368:Human T-lymphotropic virus 1 / Q000235:genetics; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality; D011241:Prednisone / Q000627:therapeutic use; D000068898:Raltegravir Potassium / Q000008:administration & dosage; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000068898:Raltegravir Potassium; D014750:Vincristine; D000069286:Bortezomib; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone